Avance Clinical Strengthens Global Oncology Offering with Acquisition of U.S-Based LumaBridge

The combination enhances Avance’s ability to support oncology development, from early Phase I studies through to global later phase programs. Clients will benefit from an expanded U.S. footprint, deeper medical, scientific, and regulatory expertise, and strong site and investigator relationships. The acquisition also strengthens Avance’s ability to provide clients with access to the Phase I market in Australia and New Zealand and further taking the innovations into Phase II and III trials through the company’s GlobalReady program.

The combined organization will continue to focus on medical, scientific, and regulatory leadership, best practices, and high-quality oncology program delivery.

“LumaBridge brings strategic oncology expertise and strong relationships with investigators and sites across the United States,” said Mark Harvill, Chief Executive Officer, Avance Clinical. “Through this combination, we will be actively serving more than 50 biotechs developing leading oncology therapies by accelerating development starting in the Australia/New Zealand region and partnering with them through phase II and beyond to their ultimate inflection point. We look forward to working as one team to help advance these important therapies for patients.”

About Avance Clinical

Avance Clinical is the largest premium full-service Australian headquartered CRO delivering high-quality clinical trials in Australia, New Zealand, Asia, North America, and Europe for international biotechs. The company has won multiple Frost & Sullivan CRO Market Leadership and Customer Value Leadership Awards. With over 30 years of experience and deep expertise across more than 250 indications, Avance Clinical provides services from pre-clinical to later-phase trials, supported by best-in-class regulatory, clinical, and operational expertise.

About LumaBridge

LumaBridge is a specialty clinical research organization (CRO) focused on creating innovative oncology-focused clinical trial solutions for biotech companies. Founded in 2014 as Cancer Insight, the company offers customized clinical trial design, clinical development strategies, strategic partnership, and personalized attention to each sponsor, accelerating the development of novel oncologic therapies.

For more information, visit AvanceCRO.com and LumaBridge.com.